Dr. Webster L Santos' lab at Virginia Tech focuses on developing new therapies for chronic kidney disease (CKD), particularly aimed at reducing kidney fibrosis, a major complication of CKD. They investigate the role of sphingosine-1-phosphate (S1P) signaling in kidney health and aim to improve the design of inhibitors that can both halt and potentially reverse kidney damage. The ultimate goal is to create effective drugs for CKD that could lead to better patient outcomes and lower healthcare costs.